Feedback
Settings

Settings

Goto Application

972,323 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 97,233
1.P20250954MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
HR - 10.10.2025
Int.Class C07K 14/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
20from Spirochaetales (O), e.g. Treponema, Leptospira
 Appl.No P20250954T Applicant Valneva Austria GmbH Inventor Urban Lundberg
2.P20250974OLIGOMERS AND OLIGOMER CONJUGATES
HR - 10.10.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No P20250974T Applicant F. HOFFMANN - LA ROCHE AG Inventor Hassan Javanbakht
3.WO/2025/208856USE OF RECOMBINANT HUMAN ELASTIN PEPTIDE WITH ANTI-AGING EFFECTS AND COMPOSITION THEREOF
WO - 09.10.2025
Int.Class C07K 14/78
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin
 Appl.No PCT/CN2024/129480 Applicant HANGZHOU ENHE BIOTECHNOLOGY CO., LTD. Inventor SHAO, Qimiao
Relating to the field of biotechnology, disclosed are a recombinant human elastin peptide with anti-aging effects and a use thereof. The recombinant human elastin peptide comprises an amino acid sequence shown in SEQ ID NO:1 or a fragment of the amino acid sequence shown in SEQ ID NO:1, the fragment comprises 30% or more of SEQ ID NO:1, or a mutant of the amino acid sequence shown in SEQ ID NO:1 or the fragment of the amino acid sequence shown in SEQ ID NO:1. A disclosed method for producing elastin peptides by using a yeast expression system enables the targeted synthesis of highly effective protein fragments with 100% homology to human proteins, while achieving low costs and facilitating large-scale production, avoiding animal-derived sources and viral risks. This makes the recombinant human elastin peptide safe for use as an anti-aging and anti-photoaging active ingredient in cosmetics, while also supporting a use thereof in the field of biomedical materials.
4.WO/2025/210521LIPID NANOPARTICLES FOR STIMULATING T CELLS
WO - 09.10.2025
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
 Appl.No PCT/IB2025/053436 Applicant GENEVANT SCIENCES GMBH Inventor DALY, Owen
The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating CD8+ T cells associated with protein or protein fragments of interest. The lipid nanoparticles can have a negative zeta potential and/or particular configurations and/or relative amounts of a phospholipid, an ionizable lipid, and a conjugated lipid. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.
5.WO/2025/210536DOSE-DEPENDENT ADMINISTRATION OF INHIBITOR OF PNPLA3 EXPRESSION
WO - 09.10.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/IB2025/053464 Applicant ASTRAZENECA AB Inventor NIAZI, Mohammad
The present disclosure provides a method of treating a subject having or at risk of developing a liver disease, the method comprising administering to the subject a composition comprising about 10 mg to about 90 mg of an inhibitor of patatin-like phospholipase domain-containing protein 3 (PNPLA3) expression and a pharmaceutically acceptable carrier and/or excipient, wherein, the inhibitor of PNPLA3 expression comprises an antisense oligonucleotide comprising a nucleobase sequence complementary to a region of a nucleic acid encoding PNPLA3. In some embodiments, the methods and dosage forms are useful for treating, preventing, or ameliorating a disease associated with PNPLA3 in a subject having an I148M mutation.
6.WO/2025/212981ORTHOGONAL AMINOACYL TRNA SYNTHETASE PAIRS FOR PROTEIN PRODUCTION
WO - 09.10.2025
Int.Class C12N 9/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
 Appl.No PCT/US2025/023093 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor RADFORD, Felix
The present disclosure relates to orthogonal transfer RNA and aminoacyl tRNA synthetase pairs that can be used in a heterologous host cell to produce a protein of interest.
7.WO/2025/213056GENE THERAPY FOR STXBP1 ENCEPHALOPATHY
WO - 09.10.2025
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No PCT/US2025/023210 Applicant CAPSIDA BIOTHERAPEUTICS, INC. Inventor XUE, Mingshan
The disclosure concerns compositions and methods for treatment of encephalopathies, including encephalopathies caused by, or associated with, and STXBP1 haploinsufficiency or mutation. Compositions and methods provided herein encompass AAV particles that encapsidate the STXBP1 transgene and allow for STXBP1 expression, including expression of STXBP1 in central and/or peripheral nervous system cells.
8.WO/2025/210641INTERLEUKIN 1-RECEPTOR ANTAGONIST WITH INCREASED SOLUBILITY AND PROCESS OF PREPARATION THEREOF
WO - 09.10.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/IN2024/050358 Applicant COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH Inventor BHAMBURE, Rahul Sharad
The present invention is directed to the cells, compositions, and methods for the production of and purification of recombinant protein. In particular, the invention is directed to have enhanced soluble expression of interleukin 1-receptor antagonist by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. The invention also provides a method for increased production and purification of interleukin 1-receptor antagonist (IL-1Ra) wherein, the polynucleotide of the present invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. The invention also relates to the purification method for of interleukin 1-receptor antagonist (IL-1Ra) using multimodal chromatography as well as characterization of properly folded of interleukin 1-receptor antagonist (IL-1Ra) protein.
9.WO/2025/210011ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LIVER DISEASE
WO - 09.10.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/058808 Applicant PROQR THERAPEUTICS II B.V. Inventor HOLKERS, Maarten
The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule, preferably an RNA transcript molecule, in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule form the SLC10A1 gene that encodes the Na+/Taurocholate Co-transporting Polypeptide (NTCP), and the target adenosine is the adenosine in the GAC codon coding for aspartic acid (D) at position 24 of the NTCP protein. The deamination of the adenosine changes the amino acid to a glycine (G). The RNA editing of the adenosine will result in a loss-of-function of the NTCP protein, which will result in lowered uptake of bile acids from the portal circulation into the liver, thereby lowering the risk of suffering from disorders related to bile accumulation in the liver.
10.20250312422COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS
US - 09.10.2025
Int.Class A61K 38/45
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
45Transferases (2)
 Appl.No 18953159 Applicant Translate Bio MA, Inc. Inventor Balkrishen Bhat

Provided herein are compositions and methods for facilitating or enhancing delivery of nucleic acids, such as synthetic mRNAs, into cells or tissues. Such compositions and methods may include use of a targeting moiety-conjugated, such as an N-acetylgalactosamine (GalNAc)-conjugated, oligonucleotide to facilitate or enhance delivery.

# -